ICP
AMGN icon

Ironvine Capital Partners’s Amgen AMGN Stock Holding History

Ironvine Capital Partners’s Portfolio AMGN Stock Details AMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,642
Closed -$280K – 70
2018
Q1 		$280K Hold
1,642
– – 0.07% 79
2017
Q4 		$286K Buy
+1,642
New +$291K 0.09% 80

Other funds holding AMGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ironvine Capital Partners's AMGN Position: Q2 2018 in Review

Ironvine Capital Partners sold out of Amgen (AMGN) in Q2 2018, closing a stake of 1,642 shares — an estimated $280K sold.

Ironvine Capital Partners first reported a position in AMGN in Q4 2017 and held it in 2 quarters. The position peaked at $286K in Q4 2017. 1,763 funds tracked by Wall St. Rank hold AMGN as of Q2 2018.

  • Ironvine Capital Partners reported no remaining Amgen position as of Q2 2018 after selling out during the quarter.
  • Ironvine Capital Partners sold 1,642 Amgen shares in Q2 2018, an estimated $280K.
  • Ironvine Capital Partners first reported a position in Amgen in Q4 2017 and held it in 2 quarters.
  • Ironvine Capital Partners's Amgen position peaked at $286K in Q4 2017.
  • 1,763 funds tracked by Wall St. Rank held Amgen as of Q2 2018.

Based on Ironvine Capital Partners's 13F filing for Q2 2018, filed 26 Jul 2018.